Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Mali Med ; 38(1): 7-11, 2022.
Artigo em Francês | MEDLINE | ID: mdl-38506202

RESUMO

INTRODUCTION: The pure digestive form of COVID-19 is possible and initially considered rare. Our objectives were to determine the frequency of COVID-19 in patients treated in general surgery, identify the circumstances of COVID-19 discoveries in surgery, describe the post-operative complications in patients operated on COVID-1919 and describe the reorganization of post-operative COVID-19 diagnosis management. MATERIALS AND METHODS: We conducted a prospective descriptive study from March 2020 to August 2021 (18 months). All patients who have been operated on, hospitalized or consulted in the department, the Emergency Department (ERS) or other CHU-GT departments for surgical pathology with COVID-19 or infected with COVID-19 while hospitalized were included in the study. RESULTS: 23 cases collected, representing 8.91% (23/258) of COVID-19 cases identified, a frequency of 1.27/month. The age group 66-75 was the most affected, the average age was 49.13 18.75 years, the predominance was male (sex ratio of 1.3). More than 34.78% were recruited at the SAU, 16 patients (69.56%) consulted in emergency, and digestive signs of COVID-19 were: Abdominal pain 20 cases (89.96%), anorexia 19 cases (82.61%), vomiting 8 cases (34.78%) and diarrhea 3 cases (13.04%). The pulmonary signs of COVID-19 were: Cough 18 cases (78.26%), chest pain 15 cases (65.22%), and dyspnea 9 cases (39.13%). Manifestations of COVID-19 were: pulmonary 9 cases, digestive 9 cases, associated 3 cases, incidental discovery 2 cases. The diagnostic mean was Thoracic CT (100%), Test-PCR 14 cases (60.86%) with a positive PCR test in 50% of cases. Surgical pathologies were surgical emergencies in 7 cases (30.43%), cancers in 6 cases (26.09%), COVID-19 digestive event (30.43%) and other 3 cases (13.04%). More than half of patients were operated on 12 cases (52.17%). The overall mortality was 60.87% and the mortality of surgical patients was 41.67%. CONCLUSION: The infectious risk of COVID-19 during hospitalization, during or after digestive surgery is a real and potentially serious risk for the patient and caregivers.


INTRODUCTION: La forme digestive pure de la COVID-19 est possible et initialement considérée comme rare. L'objectif était d'étudier la COVID-19 en milieu chirurgical. MATÉRIELS ET MÉTHODES: L'étude était descriptive prospective de Mars 2020 à Aout 2021 (18 mois). Tous les patients qui ont été opérés, hospitalisés ou consultés dans le service, au service d'accueil des urgences (SAU) ou dans d'autres services du CHU. GT pour pathologie chirurgicale avec COVID-19 ou infecté au COVID-19 en cours d'hospitalisation étaient inclus dans l'étude. RÉSULTATS: 23 cas colligés ; représentant 8,91 % (23/258) des cas de COVID-19 recensés, une fréquence de 1,27/mois. La tranche d'âge 66-75 ans était la plus atteinte, la moyenne d'âge était de 49,13 ± 18,75ans, la prédominance était masculine (sex-ratio de 1,3). Plus de 34,78% ont été recrutés au SAU, 16 malades (69,56%) ont consultés en urgence, les signes digestifs du COVID-19étaient : Douleur abdominale 20 cas (89,96%), anorexie 19 cas (82,61%), Vomissements 8 cas (34,78%), diarrhée 3 cas (13,04%). Les signes pulmonaires du COVID-19 étaient : Toux 18 cas (78,26%), douleur thoracique 15 cas (65,22%), dyspnée 9 cas (39,13%). Les manifestations du COVID-19 étaient : pulmonaire 9 cas, digestives 9 cas, associées 3 cas, découverte fortuite 2 cas. Le moyen diagnostic a été la TDM Thoracique (100%), le Test-PCR 14 cas (60,86%) avec un test-PCR positif dans 50% des cas. Les pathologies chirurgicales étaient des urgences chirurgicales dans 7 cas (30,43%), des cancers dans 6 cas (26,09%), manifestation digestive COVID-19(30,43%), autres 3 cas (13,04%).Plus de la moitié des malades étaient opérés 12 cas (52,17%). La mortalité globale était de 60,87% et la mortalité des malades opérés était de 41,67%. CONCLUSION: Les pathologies chirurgicales et COVID-19 n'étaient pas fréquentes. La plupart des malades avaient plus de 50 ans avec une présence moyenne de comorbidité. Les signes pulmonaires étaient les plus marquants, cependant les signes digestifs étaient inaugurales dans la moitié des cas de notre étude. La TDM Thoracique associée ou non au Test-PCR oro-pharyngé permet de faire le diagnostic. Le traitement peut-être médico-chirurgical ou médical. Le risque infectieux de la COVID-19 au cours de l'hospitalisation, pendant ou après la chirurgie est réel et potentiellement grave pour le malade ainsi que les soignants.

2.
Arch Neurol ; 66(1): 85-91, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19139304

RESUMO

OBJECTIVE: To describe the spectrum of clinical symptoms, signs, and laboratory features associated with A3243G, a mitochondrial DNA point mutation that affects multiple organs with varying severity, making the diagnosis and treatment of these patients complex. DESIGN: Cohort study. SETTING: Columbia University Medical Center. PARTICIPANTS: A cohort of 123 matrilineal relatives from 45 families, including 45 fully symptomatic patients with mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (syndrome), 78 carrier relatives, and 30 controls. MAIN OUTCOME MEASURES: Data gathered from standardized medical history questionnaires, neurological and ophthalmological examination forms, and laboratory tests. We compared data between 3 groups. RESULTS: Mutation carriers' clinical and laboratory results frequently had many abnormalities. In addition to neurological symptoms, they often had cardiac, endocrine, gastrointestinal, and psychiatric symptoms. CONCLUSIONS: The A3243G mutation carriers have multiple medical problems, suggesting that the A3243G mutation should be considered as an etiological factor in patients with multisystem clinical presentations or a family history compatible with matrilineal inheritance. Because some medical problems affecting A3243G mutation carriers are treatable, early detection and proactive management may mitigate the burden of morbidity.


Assuntos
DNA Mitocondrial/química , Síndrome MELAS/diagnóstico , Síndrome MELAS/genética , Mutação , Adolescente , Adulto , Criança , Pré-Escolar , Estudos de Coortes , Análise Mutacional de DNA , Diagnóstico Precoce , Feminino , Predisposição Genética para Doença , Testes Genéticos , Genótipo , Heterozigoto , Humanos , Padrões de Herança , Masculino , Pessoa de Meia-Idade , Fenótipo , Inquéritos e Questionários , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA